TOKYO, Mar 23 (Pulse News Wire) – HEALIOS K.K. (4593.T) reported a significant decrease in revenue to ¥560 million for the fiscal year ending December 2025 compared to ¥1.042 billion in the previous year.
Research and development expenses increased by ¥60 million, leading to a net loss of -¥2.220 billion. Despite the decline, the company secured approximately ¥60 million through the issuance of new shares and warrants, improving its cash position to exceed ¥10 million. HEALIOS continued to make progress in its pipeline, particularly with HLCM051, which showed promising results in clinical trials for acute respiratory distress syndrome (ARDS). The company signed agreements with Minaris and Alfresa to advance commercial production and distribution within Japan.
Additionally, HEALIOS entered into a supply contract with AND Medical Group for cell culture supernatants used in novel treatments and cosmetics. Looking ahead, HEALIOS plans to allocate funds raised towards further development of HLCM051 and operational needs until 2028. The company also highlighted potential risks associated with long-term development costs and regulatory approval processes but emphasized ongoing efforts to mitigate these challenges through strategic partnerships and resource optimization. HEALIOS remains committed to enhancing its financial stability while advancing its therapeutic solutions aimed at improving patient outcomes.
🟡 Confidence: Standard AI-translated content.